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(AD) is challenging, with a 70.9%–87.3% sensitivity
and 44.3%–70.8% speciﬁcity, compared with autopsy
diagnosis. Florbetapir F18 positron emission tomogra-
phy (FBP-PET) estimates beta-amyloid plaque density
antemortem. Methods: Of 2052 patients (Z55 years
old) clinically diagnosed with mild or moderate AD
dementia from 2 solanezumab clinical trials, 390 opted
to participate in a FBP-PET study addendum. We
analyzed baseline prerandomization characteristics.208 www.psychosomaticsjournal.orgwhereas 72.5%ofmild and 86.9%ofmoderateADpatients
had positive results. No baseline clinical variable reliably
differentiated negative from positive FBP-PET scan
groups. Conclusions: These data conﬁrm the challenges of
correctly diagnosing AD without using biomarkers. FBP-
PET can aid AD dementia differential diagnosis by
detecting amyloid pathology antemortem, even when the
diagnosis of AD is made by expert clinicians.
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Accurate diagnosis of the causes of cognitive impair-
ment allows physicians, patients, and patients’ families
to manage treatments for the underlying disorder(s)
and develop a more focused plan for future psycho-
social and medical needs.1–4 Additionally, patients
appreciate receiving the diagnosis.5 Among the top
4 causes for dementia, Alzheimer disease (AD) is the
most common followed by vascular, Lewy body, and
frontotemporal dementias.6 The clinical diagnosis of
AD is challenging and often not made in a timely
fashion, especially by primary care physicians who
may wait for several years to make and communicate
the diagnosis to those affected and their family
members, in part, due to uncertainty.7–9 Care must
be taken to include a thorough assessment of signs and
symptoms, as well as central nervous system andmedical conditions known to cause or mimic demen-
tia. Blood tests and structural (head computerized
tomography (CT) or magnetic resonance imaging
(MRI)) and functional positron emission tomography
(PET) neuroimaging using ﬂuorodeoxyglucose
(FDG)-PET are commonly used during differentialPsychosomatics 57:2, March/April 2016
Degenhardt et al.diagnosis, along with neuropsychologic testing. Cer-
ebrospinal ﬂuid (CSF) measurement of soluble AD
biomarkers for soluble amyloid-beta (β) and tau is
clinically available, but results are not widely stand-
ardized and patient acceptance of lumbar puncture
varies. Newer PET technology that detects β-amyloid
plaque in the living brain is more recently increasing in
availability and use. Tau PET is under development
and not yet ready for use in clinical practice.
β-Amyloid neuropathologic changes character-
istic of AD occur decades before the ﬁrst clinical
symptoms appear.10,11 A number of medications
currently in development for potential disease mod-
iﬁcation target the amyloid cascade. In addition, the
ﬁeld is moving toward making and communicating an
accurate diagnosis of AD earlier, as it may decrease
medical costs,12 help families understand the need
for intervention and support, and increase the like-
lihood for patient involvement in future decisions about,
for example, their health care, ﬁnances, and other life
plans.13
Clinically, the diagnosis of AD dementia is made
by assessing cognitive, language, and functional abil-
ities using the International Classiﬁcation of Diseases,
tenth revision (ICD-10), Diagnostic and Statistical
Manual of Mental Disorders 4th Edition (DSM-IV),
and National Institute of Neurological and Commu-
nicative Disorders and Stroke and the Alzheimer
Disease and Related Disorders Association (NINCDS/
ADRDA) criteria.14 However, a deﬁnitive diagnosis
of AD is made only by neuropathologic examination,
at autopsy or rarely with brain biopsy. When data
from the National Alzheimer Coordinating Center
were analyzed to determine accuracy of a clinical
diagnosis for possible or probable AD dementia vs
neuropathologic ﬁndings characteristic of AD at
autopsy, sensitivity ranged from 70.9%–87.3% and
speciﬁcity ranged from 44.3%–70.8%, depending on
the levels of clinical and neuropathologic criteria
used.15 In 82 elderly patients in the OPTIMA study,
the agreement between clinical and ﬁnal clinico-
neuropathologic diagnosis using the Consortium to
Establish a Registry for Alzheimer Disease was sub-
stantial (κ ¼ 0.7), when possible and probable AD
categories were combined.16
Because knowledge about the clinical manifesta-
tions and biology of AD has increased considerably,
the long-standing NINCDS/ADRDA criteria for AD
were revised in 2011. Changes were made in thePsychosomatics 57:2, March/April 2016clinical criteria for diagnosis, and biomarker evidence
was integrated into the diagnostic formulations for
probable and possible AD dementia for use in research
settings.17 Suggested biomarkers include those from 2
categories: β-amyloid related including CSF Aβ-1-42
levels and amyloid PET neuroimaging, and neuro-
degeneration including CSF-tau and phospho-tau lev-
els, FDG-PET,MRI.The apolipoproteinE ε4 genotype
(APOE4) is the most robust genetic risk factor for
sporadic late-onset AD, but it is not an absolute
predictor even in patients with APOE4 homozygote
status who are at very high risk to develop AD.18
A total of 3 PET radiotracers for β-amyloid plaque
detection are currently approved by the Food and
DrugAdministration, including ﬂorbetapir F18 (FBP)
PET, as a diagnostic tool for patients with cognitive
impairment suspected of having AD.19,20 FBP-PET
visual interpretation and quantitative estimates of
cortical amyloid plaques correlated with the presence
and quantity of β-amyloid pathology at autopsy,
respectively.19 FBP can be used to distinguish indi-
viduals with sparse to no amyloid plaques from those
with moderate to frequent amyloid plaques using a
visual binary interpretation of the PET scan.21 The
FBP-PET positive or negative scans have also been
deﬁned in research using a cutoff on the standardized
uptake value ratio (SUVR), a quantitative analysis of
the ratio of cortical to cerebellar signal.21,22
We report a post hoc analysis of patients with a
clinical diagnosis of mild or moderate probable AD
dementia by dementia experts who participated in
biomarker substudies in 2 registration clinical trials of
solanezumab. We investigated whether prerandom-
ization clinical characteristics, cognitive, neuropsychi-
atric, or functional scores differed between patients
with or without clinically signiﬁcant β-amyloid plaque
deposition as measured with FBP-PET. The purpose
was to ascertain whether any clinically available
characteristics could have reliably distinguished the
amyloid status of patients.
MATERIAL AND METHODS
Patients and Design
Study data are for a subset of patients (n ¼ 390)
among 2052 patients from 2 nearly identical solanezu-
mab registration trials23 pooled for this cross-sectional,
post hoc analysis. Patients in this report were Z55www.psychosomaticsjournal.org 209
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dementia and opted to participate in an FBP-PET
scan study addendum at sites with PET imaging
centers. Demographic, cognitive, neuropsychiatric,
genetic, and FBP-PET images were obtained at
baseline before randomization to drug. Amyloid
positivity was not a study entry criterion. Both trials
had identical entry criteria and enrolled medically
stablemale and female patients with probableADper
NINCDS/ADRDA criteria.24 Inclusion criteria were
the following: Modiﬁed Hachinski Ischemia Scale
r4, Geriatric Depression Scale (GDS) short form
r6, and Mini-Mental State Examination (MMSE)
between 16 and 26 inclusive. Other inclusion criteria
were MRI or CT scan performed within the previous
2 years with no ﬁndings inconsistent with a diagnosis
of AD. Patients were permitted to be on concurrent
medications for AD if they had been on the medi-
cation for at least 4 months and at a stable dose for at
least 2 months before study randomization. About
89% of patients were taking cholinesterase inhibitors
(such as donepezil, galantamine, rivastigmine, or
tacrine) with or without memantine at the time of
study entry. Our trial designs deﬁned mild AD
dementia as MMSE scores of 20–26 (inclusive) and
moderate as MMSE 16–19.23
All patients and caregivers provided written
informed consent according to the Declaration of
Helsinki, and the study procedures were approved by
the institutional review boards. A complete descrip-
tion of the primary studies can be found in Doody
et al.23Neuropsychiatric and Functional Assessment
Various assessment tools including measures of
cognition, global functioning, and psychopathology
were administered at baseline. The Alzheimer Dis-
ease Assessment Scale-Cognitive Subscale, 14-item
version (ADAS-Cog14)25,26 measures dysfunction in
cognitive domains, such as orientation, verbal mem-
ory, language, praxis, and executive function. The
score ranges from 0–90, with higher scores indicating
greater impairment. The Alzheimer Disease Coop-
erative Study Activities of Daily Living (ADCS-
ADL) Inventory,27 (ADCS-ADL) is a 23-item scale
that assesses eating, bathing, walking, reading, shop-
ping, and managing money. Scores range from 0–78,
with higher scores indicating greater independence in210 www.psychosomaticsjournal.orgthe performance of activities of daily living (ADLs).
The Clinical Dementia Rating–Sum of Boxes (CDR-
SB)28 evaluates cognition and functional perform-
ance in 6 domains including memory, orientation,
judgment and problem solving, home and hobbies,
community affairs, and personal care. The scores in
each of the 6 areas are summed to yield CDR-SB
scores ranging from 0–18, in which higher scores
indicate more severe impairment. The MMSE29 is a
multidomain ofﬁce-based cognitive test that assesses
orientation, memory, attention, visuoconstructional
ability, naming, and the ability to follow written and
oral commands with scores ranging from 0 (very
impaired)–30 (normal). The Neuropsychiatric Inven-
tory (NPI)-1230 measures frequency and severity of
psychopathology in neurologically-impaired patients
including delusion, hallucination, agitation or
aggression, apathy, anxiety, depression, euphoria,
irritability or lability, disinhibition, aberrant motor
behavior, and neurovegetative changes, such as
appetite and nighttime behavior disturbances. Scores
range from 0 (mild)–144 (severe). The NPI subscales
for agitation or aggression, frontal symptoms, and
mood symptoms have been validated using principal
component analysis.31 The GDS32 is a 15-item
measure for depressive symptoms with scores ranging
from 0–15 (more symptoms), in which a 7-point
cutoff indicates syndromal depression.FBP-PET Neuroimaging
At baseline before drug randomization, PET neuro-
imaging was performed after the intravenous
administration of 370 MBq of F18-FBP. Images were
obtained and emission data were collected, corrected
for attenuation, and reconstructed using the
3-dimensional maximum a priori method speciﬁed
in the studies’ protocols.23 The SUVR was calculated
as the ratio of the mean of 6 cortical regions of interest
(frontal, temporal, precuneus, parietal, anterior cin-
gulate, and posterior cingulate), relative to the whole
cerebellum reference region with a threshold for
amyloid positivity of 41.10.19,21,22Laboratory Analyses
APOE4 genotype was determined as a part of the
serum biochemical measurements and hematologicPsychosomatics 57:2, March/April 2016
Degenhardt et al.analyses used in the original trials to analyze for effects
of APOE4 carrier status.
Statistical Analyses
All statistical analyses were performed using SAS
9.2 (Cary, NC). Descriptive statistics used means and
standard deviations. Demographic, rating scale, genetic
(APOE4 status), and cognitive data were compared by
either 2-tailed Fisher’s exact test (for categorical varia-
bles) or analysis of variance (ANOVA, for continuous
variables) between patients categorized as positive or
negative for β-amyloid on FBP-PET. This comparison
was conducted separately for 3 groups of patients: all
patient, patients with mild AD dementia, and patients
with moderate AD dementia. Pearson correlations were
performed between composite SUVRwith age and years
of education for the entire cohort. Statistical signiﬁcance
was set at po 0.05.
RESULTS
Demographic Characteristics
Of 390 mild and moderate probable AD dementia
patients, 87 (22.4%) were found to be FBP-PET
negative (Table). The negative scan group had a
signiﬁcantly lower proportion of females (43.7% vs
56.3%; p ¼ 0.0145) than the positive scan group.
Baseline age and education were similar between the
scan groups, though disease duration since onset of
symptoms was signiﬁcantly longer in the positive
group (p ¼ 0.0056).
Positive FBP-PET scans occurred in 72.5% of the
mild vs 86.9% of the moderate AD dementia group
(p ¼ 0.0014). In the mild group, those with negative
scans were signiﬁcantly younger than those with
positive (p ¼ 0.0051).Clinical Characteristics
There was less severe cognitive impairment in the
negative compared with positive scan group as indi-
cated by mean ADAS-Cog14 (28.2  12.1 vs 35.2 
10.7; p o 0.0001) and MMSE scores (22.2  3.1 vs
20.5  3.0; p o 0.0001).
MMSE scores were signiﬁcantly different between
scan groups only in the mild dementia group (p ¼
0.0005). Among the MMSE domains, orientation andPsychosomatics 57:2, March/April 2016recall were signiﬁcantly worse in the amyloid-positive
group (po 0.0001 and p¼ 0.0003), again driven by the
mild dementia group. Similar to MMSE, the only
difference for ADAS-Cog14 was in the mild dementia
group where those with negative scans had signiﬁ-
cantly better scores than those with positive scans (po
0.0001).
More years of education (r¼ 0.1835; p¼ 0.0003),
but not age (r ¼ 0.0388; p ¼ 0.4449), correlated
signiﬁcantly with higher FBP-PET SUVR indicating
amyloid burden.
A signiﬁcantly smaller proportion of the negative
scan group was APOE4 carriers (22.62% vs 62.85%;
po 0.001). Homozygotes for the APOE4 allele were
highly likely to be amyloid positive (mild ¼ 100.00%,
moderate ¼ 95.83%).
No differences were found between positive
and negative scan groups or their mild AD subgroups
on ADCS-ADL, CDR-SB, NPI, or GDS.DISCUSSION
We retrospectively analyzed pooled clinical and FBP-
PET scan data from baseline visits for 390 clinical trial
patients who had been clinically diagnosed as having
mild or moderate probable AD dementia. About one-
ﬁfth (22.4%) of patients did not have evidence of
β-amyloid plaque pathology despite having received a
clinical diagnosis of AD by expert physicians partic-
ipating in therapeutic clinical trials. Considering only
the mild dementia cases, 27.5% had negative FBP-
PET scans, consistent with the literature that earlier
phases ofADaremore difﬁcult to diagnose accurately.
Though clinically evaluated before enrollment to rule
out other causes for their cognitive impairment (e.g.,
vascular dementia, Parkinson’s disease, major depres-
sion), these patients who are amyloid-negative pre-
sented with the AD clinical phenotype yet lacked
sufﬁcient β-amyloid plaque density on FBP-PET scans
to support their AD diagnosis. The cause of their
dementia is not known as part of this research but
possibilities include tauopathies, frontotemporal de-
mentia, and hippocampal sclerosis.
It is possible to have false-positive or false-negative
PET scan results, though the pivotal FBP-PET
registration trials showed very high concordance
with AD neuropathologic autopsy diagnoses, including
96% sensitivity and 100% speciﬁcity in thosewww.psychosomaticsjournal.org 211
TABLE. Comparison of Baseline Variables Between Positive FBP-PET and Negative FBP-PET Scan Groups, with Values by Dementia
Stage Subgroup (N ¼ 390)
Variable Positive FBP-PETn Negative FBP-PETn p Value†
n ¼ 303 (mild ¼ 182, moderate ¼ 119) n ¼ 87 (mild ¼ 69, moderate ¼ 18)
Mean (SD) Mean (SD)
Duration of diagnosis (years) 2.38 (1.92) 2.06 (1.88) 0.1804
Mild 2.14 (1.82) 1.68 (1.57) 0.0659
Moderate 2.75 (2.02) 3.54 (2.26) 0.1304
Duration of disease onset (years) 4.75 (2.55) 3.92 (2.06) 0.0056
Mild 4.55 (2.43) 3.70 (2.08) 0.0107
Moderate 5.09 (2.71) 4.78 (1.81) 0.6367
Years of formal education 13.13 (3.64) 12.32 (4.73) 0.0888
Mild 13.54 (3.28) 12.78 (4.62) 0.1464
Moderate 12.49 (4.07) 10.56 (4.87) 0.0699
Modiﬁed Hachinski Ischemia Scale 0.69 (0.76) 0.84 (0.85) 0.1077
Mild 0.66 (0.74) 0.84 (0.88) 0.1022
Moderate 0.71 (0.76) 0.83 (0.71) 0.5063
Age (years) 75.23 (8.37) 73.25 (9.14) 0.0587
Mild 75.26 (8.41) 71.81 (9.17) 0.0051
Moderate 75.25 (8.35) 78.78 (6.76) 0.0900
ADAS-Cog14 35.23 (10.65) 28.16 (12.09) o0.0001
Mild 31.73 (9.83) 24.22 (8.52) o0.0001
Moderate 40.44 (9.71) 43.28 (12.01) 0.2646
CDR-SB 5.02 (2.13) 4.68 (2.83)‡ 0.2256
Mild 4.43 (1.67) 3.93 (2.25) 0.0555
Moderate 5.89 (2.42) 7.53 (3.04) 0.0111
ADCS-ADL 60.83 (11.11) 59.57 (15.31) 0.3986
Mild 63.30 (10.19) 63.14 (13.35) 0.9205
Moderate 57.13 (11.51) 45.89 (14.92) 0.0003
ADCS-ADL instrumental 39.96 (9.86) 39.53 (13.15) 0.7398
Mild 42.23 (9.01) 42.54 (11.72) 0.8262
Moderate 36.61 (10.18) 28.00 (12.16) 0.0014
ADCS-ADL basic 20.84 (2.10) 20.02 (2.98) 0.0040
Mild 21.04 (2.02) 20.61 (2.24) 0.1406
Moderate 20.51 (2.19) 17.78 (4.26) o0.0001
NPI—12 8.8 (10.37)§ 7.63 (12.14) 0.3724
Mild 7.64 (9.70) 6.86 (10.50) 0.5764
Moderate 10.52 (11.13) 10.61 (17.11) 0.9765
NPI-4 agitation subscale 2.78 (4.97)§ 1.87 (3.76) 0.1143
Mild 2.47 (4.87) 1.71 (3.18) 0.2310
Moderate 3.30 (5.14) 2.50 (5.54) 0.5420
NPI-3 mood subscale 2.95 (4.66) 2.41 (4.82) 0.3482
Mild 2.35 (3.53) 2.26 (4.28) 0.8723
Moderate 3.88 (5.92) 3.00 (6.61) 0.5629
NPI-4 frontal subscale 2.90 (4.26) 2.47 (4.02) 0.3978
Mild 2.73 (4.34) 2.20 (3.72) 0.3772
Moderate 3.14 (4.13) 3.50 (5.00) 0.7403
MMSE 20.48 (3.01) 22.21 (3.07) o0.0001
Mild 22.54 (1.86) 23.48 (1.91) 0.0005
Moderate 17.43 (1.19) 17.33 (1.19) 0.7521
MMSE attention and calculation 2.67 (1.66) 2.82 (1.55) 0.4627
Mild 3.20 (1.57) 3.07 (1.53) 0.5523
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TABLE. Continued
Variable Positive FBP-PETn Negative FBP-PETn p Value†
n ¼ 303 (mild ¼ 182, moderate ¼ 119) n ¼ 87 (mild ¼ 69, moderate ¼ 18)
Mean (SD) Mean (SD)
Moderate 1.87 (1.47) 1.83 (1.25) 0.9116
MMSE language 7.86 (1.06) 8.07 (1.07) 0.1022
Mild 8.08 (0.93) 8.26 (0.92) 0.1736
Moderate 7.52 (1.16) 7.33 (1.28) 0.5280
MMSE orientation 6.36 (1.99) 7.45 (2.10) o0.0001
Mild 7.14 (1.75) 8.06 (1.59) 0.0002
Moderate 5.19 (1.78) 5.11 (2.19) 0.8597
MMSE registration 2.92 (0.32) 2.89 (0.32) 0.3188
Mild 2.96 (0.25) 2.88 (0.32) 0.0645
Moderate 2.88 (0.39) 2.89 (0.32) 0.9467
MMSE recall 0.78 (0.98) 1.22 (1.03) 0.0003
Mild 0.98 (1.06) 1.36 (1.04) 0.0107
Moderate 0.48 (0.76) 0.67 (0.77) 0.3297
GDS 1.76 (1.45) 1.99 (1.60) 0.1987
Mild 1.86 (1.47) 1.90 (1.58) 0.8454
Moderate 1.58 (1.40) 2.33 (1.64) 0.0394
FBP-PET SUVR Composite 1.45 (0.20) 0.96 (0.08) o0.0001
Mild 1.45 (0.20) 0.96 (0.08) o0.0001
Moderate 1.46 (0.19) 0.94 (0.06) o0.0001
APOE4 positive carrier status, n (%)
Mild and moderate 181 (62.85) 19 (22.62) o0.0001
Mild 106 (62.35) 16 (24.24) o0.0001
Moderate 73 (62.93) 3 (16.67) o0.0001
APOE4 alleles, n (%)
Mild
0 64 (37.65) 50 (75.76) o0.0001
1 83 (48.82) 16 (24.24) o0.0001
2 23 (13.53) 0 (0.00) o0.0001
Moderate
0 43 (37.07) 15 (83.33) 0.0013
1 50 (43.10) 2 (11.11) 0.0013
2 23 (19.83) 1 (5.56) 0.0013
ADAS-Cog14 ¼ Alzheimer Disease Assessment Scale-Cognitive Subscale, 14-item version; ADCS-ADL ¼ Alzheimer Disease
Cooperative Study Activities of Daily Living Inventory;APOE4¼ apolipoprotein E-ε4 alleles; CDR-SB¼Clinical Dementia Rating–Sum
of Boxes; FBP-PET ¼ ﬂorbetapir-ﬂuorine-18 positron emission tomography; GDS ¼ Geriatric Depression Scale—short form; MMSE ¼
Mini-Mental State Examination; NPI¼Neuro Psychiatric Inventory; SD¼ standard deviation; SUVR¼ standardized uptake value ratio.
n FBP-PET scans were categorized as either positive or negative for the presence of abnormal levels of amyloid neuritic plaque using a
cutoff value of 1.1.
† Frequencies are analyzed using Fisher’s exact test, means by analysis of variance. Bold font indicates signiﬁcant values. Signiﬁcance set
at p o 0.05.
‡ n ¼ 86.
§ n ¼ 302.
Degenhardt et al.whose scans were performed within the year before
autopsy.19,21
Patients who are amyloid-negative with probable
AD have been reported in other AD clinical trialsPsychosomatics 57:2, March/April 2016where amyloid biomarkers have been used. In the
IDENTITY phase 3 study program using semagace-
stat and similar entry criteria, 18% of patients with
clinically diagnosed probable mild or moderate ADwww.psychosomaticsjournal.org 213
Florbetapir F18 PET Amyloid Neuroimagingdementia who had an FBP-PET scan were amyloid-
negative, where 24% of the mild dementia cases were
negative.33 In bapineuzumab clinical trials, negative-
amyloid PET scans (using C11-Pittsburgh Com-
pound-B (PiB)) were found in 22.4% of placebo
completers in phase 3 clinical registration trials and
16% in phase 1b clinical trials.34–36
Similar to Witte et al.,33 we did not ﬁnd any
clinical characteristic that could reliably predict
amyloid status even though some had statistically
signiﬁcant differences— such as disease duration.
Neuropsychiatric symptoms, including depression,
mood, agitation or aggression, and frontal symptoms,
did not differ between any of the groups. In the mild
group, the patients who are amyloid-negative were less
cognitively impaired and somewhat younger (early
70s) than the amyloid positive, without functional
differences.MMSE domains for recall and orientation
were signiﬁcantly less impaired in the amyloid-
negative mild group. Interestingly, in the moderate
group, functional impairment was greater in negative
than positive patients for both basic and instrumental
ADLs. Though these differences are interesting, they
do not form a pattern that could on its own elucidate
the underlying cause for negative-amyloid cases.
Antemortem tests may not exist yet for some of the
causes to be considered. APOE4 genotype is a well-
known risk factor for AD and amyloid deposition,
though these are not synonymous.37,38 Chiao et al.35
found that 23% of APOE4 carriers were amyloid-
negative compared with 57% of noncarriers. Salloway
et al.36 reported that a greater number of APOE4
noncarriers were PiB-PET negative (36.1%) compared
with APOE4 carriers (6.5%). Witte et al.33 also
reported that negative FBP-PET scans were more
common in APOE4 noncarriers (82%) than carriers
(18%). Similarly, we found fewer APOE4 carriers in
the FBP-PET negative vs the positive group (22.62%
vs 62.85%), and homozygotes for the APOE4 allele
were highly likely to be FBP-PETpositive (97.92%). In
a clinically diagnosed patient, APOE4 homozygosity
could be potentially useful in place of amyloid PET.
Patients in the study were diagnosed clinically with
AD using robust inclusion and exclusion criteria.
Although not all patients had amyloid PET scans,
among those who did, a positive scan in combination
with the clinical diagnosis should result in a high
likelihood of AD.214 www.psychosomaticsjournal.orgOne limitation of our report is that only a subset
(390 of 2052) patients from 2 large registration trials
were represented in this analysis, which may not be
generalizable to the community population. However,
these data do replicate prior ﬁndings by others in
which up to 18.0% of patients33 diagnosed with AD by
dementia specialists did not have supportive evidence
on amyloid PET.39
The 2 characteristic neuropathologic ﬁndings of
AD are β-amyloid plaques and neuroﬁbrillary tan-
gles, which are aggregates of abnormal forms of tau.
Although recent developments in tau PET imaging
have made it possible to visualize tau accumulation
in parts of the brain characteristic for AD, this
technology is still under development and was not
available in our studies. In this study, CSF levels of
tau were not considered because they were only
measured in a subset of patients23 and not in all of the
patients in the amyloid PET imaging group. Addi-
tionally, by the time of the dementia stage of AD,
neuroﬁbrillary tangle pathology is likely to be
present along with β-amyloid plaque. Therefore,
making use of tau imaging or measurement of
CSF-tau is of little beneﬁt to this particular study
design.
Reliable differential clinical diagnosis in demen-
tia would be helpful in communicating the course
and prognosis to patients and families, identifying
AD patients for clinical trials and in making appro-
priate treatment decisions.14 Amyloid PET imaging
is a validated and approved adjunctive biomarker in
the diagnosis of AD. Our report and that of others
form an emerging literature demonstrating that
phenotype and a thorough but conventional
dementia work-up cannot alone accurately diagnose
AD antemortem, especially during earlier disease
phases.
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